Compare Cronos Group Inc (CRON) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nomura Holdings Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.14B), while Nomura Holdings Inc trades at $9.8 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 25× Cronos Group Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | NMR | |
|---|---|---|
Market Cap | $1.14B | $28.46B |
Sector | Health | Financials |
52-Week High | $3.27 | $10.04 |
52-Week Low | $2.30 | $6.73 |
Enterprise Value | $341.13M | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.
Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.
Nomura Holdings (NMR) trades at $9.925, up 1.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst consensus leans toward Hold, with 66.67% of coverage recommending Hold and 33.33% Buy.
The outlook for NMR is supported by robust profitability and valuation metrics like a P/E of 11.59, suggesting potential undervaluation. However, risks include inconsistent cash flow from operations, rising debt-to-asset ratios, and macroeconomic sensitivity. Investors should weigh solid fundamentals against cash flow volatility and debt trends for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
